AI driven antibodies Antiverse specializes in AI-designed therapeutic antibodies for difficult targets like GPCRs and ion channels, presenting a strong value proposition for biotech and pharma partners seeking faster discovery timelines and novel modalities.

CFTR collaboration Recent collaborations and library development targeting extracellular CFTR, including a research agreement with a cystic fibrosis foundation and a focus on CFTR antibodies, create compelling cross-selling opportunities with CF drug developers and biotechs pursuing CF therapies.

Series A momentum A 9.3 million Series A with notable investors and regional funding from CCR and Development Bank of Wales signals growing financial stability and room for co-development deals or joint ventures with larger partners.

Global footprint Headquartered in Cardiff with a Boston office and a tech-enabled stack (cloud, data analytics, HR tools) supports multinational collaboration, making Antiverse a viable partner for global pharma programs requiring distributed R&D and rapid iteration.

Market positioning Positioned as a niche biotech AI design platform targeting challenging targets, Antiverse can upsell to discovery-stage and mid-stage programs seeking novel antibodies, offering accelerated design cycles and access to expert computational biology capabilities.